Compounds / Metabolic / Liraglutide

Liraglutide

Liraglutide (GLP-1 Receptor Agonist — Daily Dosing)
MetabolicFDA: FDA-APPROVED (Victoza: T2DM; Saxenda...

Overview

FDA-approved (Victoza for T2DM; Saxenda for obesity). LEADER trial demonstrated cardiovascular mortality reduction. Precedes semaglutide in GLP-1 class.

Mechanism of Action

GLP-1 receptor agonist. ~13-hour half-life requires daily dosing. C16 fatty acid chain for albumin binding. 97% homology to native GLP-1. Predecessor to semaglutide.

Molecular Profile

Molecular weight
3751.2 Da
CAS number
204656-20-2

Key Research Findings

FDA-approved (Victoza/Saxenda); daily dosing; 13h half-life; LEADER CV trial; predecessor to semaglutide.

Published Research

NEJM (2016)
Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER trial)
View source

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideCagrilintideMazdutideBioglutide
Clinical Guidance

Research data is not a treatment plan. If you are considering Liraglutide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Liraglutide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals